David Zuckerberg is Appointed VP for Quality Assurance at Advanced Viral Research Corp.

Business/Health Editors

YONKERS, N.Y.--(BUSINESS WIRE)--Sept. 20, 2001

Advanced Viral Research Corp. (OTCBB:ADVR) today announced the appointment of David Zuckerberg as Vice-President for Quality Assurance.

He will be responsible for ensuring the consistent quality of Product R, the company's lead peptide nucleic acid immunomodulator.

Zuckerberg comes to ADVR with thirty years of experience in the pharmaceutical industry. He was VP for Technical Services for 11 years at Block Drug and was responsible for ensuring the quality of Block's worldwide manufacturing operations. He also served for 4 years as VP for Quality Assurance at Block Drug.

"We are committed to provide the highest quality pharmaceutical products to patients. Mr. Zuckerberg, a highly experienced quality assurance professional who has worked closely with the FDA, underscores the importance of our commitment," stated Dr. Shalom Z. Hirschman, President and CEO of Advanced Viral Corp. "Mr. Zuckerberg is a key appointment to the management team which will advance Product R through the regulatory process."

Product R is a non-toxic peptide nucleic acid-type immunomodulator that appears to stimulate the proinflammatory responses required to combat viral infections such as AIDS and human papilloma virus and to dampen aberrant autoimmune-type inflammatory responses, such as occur in patients with rheumatoid arthritis. Therefore, Product R has been termed a "switch type" immunomodulator. Product R has shown promise in its ability to mitigate the toxic side effects of other drugs, including those used to treat HIV infection and chemotherapeutic drugs employed in the treatment of cancers.

Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for viral and other diseases.

For further information regarding Advanced Viral Research Corp., please visit our website at www.adviral.com.

Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by ADVR. Product R is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that ADVR will be able to secure the financing necessary to complete the clinical trials of Product R. ADVR undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.